Unicycive Therapeutics Inc (NASDAQ:UNCY) does about 515.73K shares in volume on a normal day but saw 4766071 shares change hands in the recent trading day. The company now has a market cap of 60.90M USD. Its current market price is $4.77, marking a decrease of -29.85% compared to the previous close of $6.8. The 52 week high reached by this stock is $11.00 whilst the lowest price level in 52 weeks is $2.02.
The consensus objective for the share price is $62.76, suggesting that the stock has a potential upside of 92.4% over the period.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 21, 2025 when Guggenheim initiated the stock to “Buy” and issued a price target of $6.
The current price level is -29.98%, -25.02%, and -17.81% away from its SMA20, SMA50, and SMA200 respectively, with the UNCY price moving above the 50-day SMA on current market day. Unicycive Therapeutics Inc (UNCY) stock is down -32.91% over the week and -18.73% over the past month. Its price is -0.63% year-to-date and -39.94% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.69 and -1.54 for whole year. Expected sales for next quarter are $2.37M, which analysts say will come at $14.76M for the current fiscal year and next year at $367.61M.
To reach the target analysts have set, the stock logically needs to grow 92.4 percent from here.
Outstanding shares total 11.97M with insiders holding 4.93% of the shares and institutional holders owning 49.60% of the company’s common stock. The company has a return on investment of -195.79% and return on equity of -2355.27%. The forward price to earnings ratio is 0.30. The beta has a value of 1.89. Price to book ratio is 5.07.
